EP3472316A4 - Anti-c5-antikörper und verfahren zur verwendung - Google Patents

Anti-c5-antikörper und verfahren zur verwendung Download PDF

Info

Publication number
EP3472316A4
EP3472316A4 EP17813418.5A EP17813418A EP3472316A4 EP 3472316 A4 EP3472316 A4 EP 3472316A4 EP 17813418 A EP17813418 A EP 17813418A EP 3472316 A4 EP3472316 A4 EP 3472316A4
Authority
EP
European Patent Office
Prior art keywords
antibodies
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP17813418.5A
Other languages
English (en)
French (fr)
Other versions
EP3472316A1 (de
Inventor
Yoshinao Ruike
Zenjiro Sampei
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of EP3472316A1 publication Critical patent/EP3472316A1/de
Publication of EP3472316A4 publication Critical patent/EP3472316A4/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP17813418.5A 2016-06-17 2017-06-16 Anti-c5-antikörper und verfahren zur verwendung Pending EP3472316A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016120325 2016-06-17
PCT/JP2017/022253 WO2017217524A1 (en) 2016-06-17 2017-06-16 Anti-c5 antibodies and methods of use

Publications (2)

Publication Number Publication Date
EP3472316A1 EP3472316A1 (de) 2019-04-24
EP3472316A4 true EP3472316A4 (de) 2020-01-08

Family

ID=59969459

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17813418.5A Pending EP3472316A4 (de) 2016-06-17 2017-06-16 Anti-c5-antikörper und verfahren zur verwendung

Country Status (19)

Country Link
EP (1) EP3472316A4 (de)
JP (3) JP6202774B1 (de)
KR (2) KR102226975B1 (de)
CN (3) CN115960223A (de)
AU (1) AU2017285763B2 (de)
BR (1) BR112018075688A2 (de)
CA (1) CA3021956A1 (de)
CL (1) CL2018003573A1 (de)
CR (1) CR20190013A (de)
EA (1) EA201990018A1 (de)
IL (2) IL300611A (de)
MX (2) MX2018015030A (de)
MY (1) MY187848A (de)
PE (2) PE20190394A1 (de)
PH (1) PH12018502354A1 (de)
SG (2) SG11201705584VA (de)
TW (4) TWI789369B (de)
UA (1) UA126561C2 (de)
WO (1) WO2017217524A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11046784B2 (en) 2006-03-31 2021-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
MX369784B (es) 2007-09-26 2019-11-21 Chugai Pharmaceutical Co Ltd Metodo de modificacion del punto isoelectrico de anticuerpos mediante la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr).
CN107551270A (zh) 2008-04-11 2018-01-09 中外制药株式会社 与多个分子的抗原反复结合的抗原结合分子
RU2658504C9 (ru) 2010-11-30 2018-08-21 Чугаи Сейяку Кабусики Кайся Антигенсвязывающая молекула, способная многократно связываться с множеством антигенных молекул
TW201809008A (zh) 2014-12-19 2018-03-16 日商中外製藥股份有限公司 抗ｃ５抗體及使用方法
DK3468990T3 (da) 2016-06-14 2024-06-24 Regeneron Pharmaceuticals Inc Anti-C5-antistoffer og anvendelser deraf
MX2018015030A (es) * 2016-06-17 2019-04-22 Chugai Pharmaceutical Co Ltd Anticuerpos anti-c5 y metodos de uso.
SG11201801024XA (en) 2016-08-05 2018-05-30 Chugai Pharmaceutical Co Ltd Therapeutic or preventive compositions for il-8-related diseases
BR112020006692A2 (pt) * 2017-10-04 2020-10-06 Alexion Pharmaceuticals, Inc. dosagem e administração de anticorpos anti-c5 para o tratamento de pacientes com glomerulonefrite membranoproliferativa
JP2021506241A (ja) 2017-12-13 2021-02-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗ｃ５抗体組み合わせ物およびその使用
CN113038967A (zh) * 2018-09-06 2021-06-25 宾夕法尼亚大学理事会 人源化抗c5抗体及其用途
CA3137907A1 (en) * 2019-04-24 2020-10-29 The Trustees Of The University Of Pennsylvania Bi-functional humanized anti-c5 antibodies and factor h fusion proteins and uses thereof
CN113563467A (zh) * 2020-04-28 2021-10-29 上海普铭生物科技有限公司 针对人补体蛋白c5的抗体及其应用
JP7494413B2 (ja) 2020-07-15 2024-06-04 ビオシオン インコーポレイテッド Ｃ５に結合する抗体及びその用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016098356A1 (en) * 2014-12-19 2016-06-23 Chugai Seiyaku Kabushiki Kaisha Anti-c5 antibodies and methods of use

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0230985Y2 (de) 1985-07-08 1990-08-21
US6074642A (en) * 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US7738506B1 (en) 2001-06-12 2010-06-15 Telefonaktiebolaget Lm Ericsson Method and system for communication
US7432356B2 (en) 2001-08-17 2008-10-07 Genentech, Inc. Complement pathway inhibitors binding to C5 and C5a without preventing formation of C5b
JP4333939B2 (ja) 2001-08-27 2009-09-16 ロード・コーポレーション トロリ線の吊架装置
DE10253331A1 (de) 2002-11-14 2004-06-03 Symrise Gmbh & Co. Kg Verwendung von trans-Pellitori als Aromastoff
US7267849B2 (en) 2004-03-02 2007-09-11 Nitto Denko Corporation Compensator for liquid crystal display
KR20080069889A (ko) 2007-03-20 2008-07-29 (주)화도 폴리에틸렌 관
EP2129681A2 (de) * 2007-03-22 2009-12-09 Novartis Ag C5-antigene und deren verwendung
KR101515650B1 (ko) 2007-04-11 2015-04-27 세키스이가가쿠 고교가부시키가이샤 가교 폴리비닐아세탈 수지의 제조 방법 및 가교 폴리비닐아세탈 수지
CN107551270A (zh) * 2008-04-11 2018-01-09 中外制药株式会社 与多个分子的抗原反复结合的抗原结合分子
UA105009C2 (uk) * 2008-08-05 2014-04-10 Новартіс Аг Композиції та способи, призначені для спрямованого впливу антитіл на білок с5 системи комплементу
KR20100054403A (ko) 2008-11-14 2010-05-25 삼성전자주식회사 온라인 공동 작문 장치 및 방법
TW201206466A (en) * 2010-03-11 2012-02-16 Rinat Neuroscience Corp Antibodies with pH dependent antigen binding
KR20150002894A (ko) * 2010-03-11 2015-01-07 리나트 뉴로사이언스 코프. ｐＨ 의존성 항원 결합을 갖는 항체
KR20110111007A (ko) 2010-04-02 2011-10-10 이화여자대학교 산학협력단 Ｌ／ｄ 광학변환 및 광학분할을 위한 옥타하이드로-바이나프톨 유도체
KR20110122011A (ko) 2010-05-03 2011-11-09 황보철종 매장 포인트 통합 관리 시스템 및 그 방법
EA028244B1 (ru) * 2012-08-13 2017-10-31 Ридженерон Фармасьютикалз, Инк. АНТИТЕЛА К PCSK9 C pH-ЗАВИСИМЫМИ ХАРАКТЕРИСТИКАМИ СВЯЗЫВАНИЯ
BR112015018438A2 (pt) * 2013-01-31 2017-07-18 Seoul Nat Univ R&Db Foundation anticorpo contra c5 e método para prevenir e tratar doenças relacionadas a complemento
US20160051673A1 (en) * 2013-03-29 2016-02-25 Alexion Pharmaceuticals, Inc. Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5
NZ631007A (en) * 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
RU2742606C2 (ru) * 2015-12-18 2021-02-09 Чугаи Сейяку Кабусики Кайся Антитела к с5 и способы их применения
MX2018015030A (es) * 2016-06-17 2019-04-22 Chugai Pharmaceutical Co Ltd Anticuerpos anti-c5 y metodos de uso.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016098356A1 (en) * 2014-12-19 2016-06-23 Chugai Seiyaku Kabushiki Kaisha Anti-c5 antibodies and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TAKU FUKUZAWA ET AL: "Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases", SCIENTIFIC REPORTS, vol. 7, no. 1, 24 April 2017 (2017-04-24), XP055399003, DOI: 10.1038/s41598-017-01087-7 *

Also Published As

Publication number Publication date
AU2017285763B2 (en) 2024-02-01
BR112018075688A2 (pt) 2019-04-02
IL263657A (en) 2019-01-31
PH12018502354A1 (en) 2019-09-23
TWI610941B (zh) 2018-01-11
WO2017217524A1 (en) 2017-12-21
KR20190009273A (ko) 2019-01-28
CR20190013A (es) 2019-03-05
TWI789369B (zh) 2023-01-11
EP3472316A1 (de) 2019-04-24
KR102226975B1 (ko) 2021-03-11
MY187848A (en) 2021-10-26
CL2018003573A1 (es) 2019-02-01
CN109312326A (zh) 2019-02-05
MX2023001360A (es) 2023-02-27
TWI807666B (zh) 2023-07-01
TW202337903A (zh) 2023-10-01
CA3021956A1 (en) 2017-12-21
JP2022091748A (ja) 2022-06-21
AU2017285763A1 (en) 2018-11-08
TW201808996A (zh) 2018-03-16
SG11201705584VA (en) 2018-05-30
RU2019100222A (ru) 2020-07-17
RU2019100222A3 (de) 2020-11-05
JP6202774B1 (ja) 2017-09-27
CN115960223A (zh) 2023-04-14
CN109312326B (zh) 2022-09-09
KR101852739B1 (ko) 2018-04-30
JP2018009021A (ja) 2018-01-18
MX2018015030A (es) 2019-04-22
PE20240825A1 (es) 2024-04-18
EA201990018A1 (ru) 2019-08-30
TW202239766A (zh) 2022-10-16
IL300611A (en) 2023-04-01
TW201809000A (zh) 2018-03-16
UA126561C2 (uk) 2022-11-02
PE20190394A1 (es) 2019-03-13
JP2017226655A (ja) 2017-12-28
SG10201800265UA (en) 2018-02-27
JP7032077B2 (ja) 2022-03-08
CN115925922A (zh) 2023-04-07

Similar Documents

Publication Publication Date Title
IL265800A (en) Anti-lag-3 antibodies and methods of using them
SG10201912879YA (en) Anti-sirp-alpha antibodies and methods of use thereof
EP3233921A4 (de) Anti-c5-antikörper und verfahren zur verwendung
EP3515478A4 (de) Antikörper für siglec-15 und verfahren zur verwendung davon
SG10201912563XA (en) Anti-tim-3 antibodies and methods of use thereof
EP3383430A4 (de) Antikörper und verfahren zur verwendung davon
EP3454900A4 (de) Cd47-antikörper und verfahren zur verwendung davon
EP3472316A4 (de) Anti-c5-antikörper und verfahren zur verwendung
HUE062436T2 (hu) Anti-trem2 antitestek és alkalmazási módszereik
EP3383914A4 (de) Anti-ox40-antikörper und verfahren zur verwendung davon
EP3280441A4 (de) Anti-sortilin-antikörper und verfahren zur verwendung davon
EP3390442A4 (de) Anti-c5-antikörper und verfahren zur verwendung
EP3177322A4 (de) Anti-trem2-antikörper und verfahren zur verwendung davon
EP3472200A4 (de) Anti-myostatin-antikörper und verfahren zur verwendung
EP3116911B8 (de) Anti-mcam-antikörper und zugehöriges verfahren zur verwendung
EP3383917A4 (de) Neuartige anti-claudin-antikörper und verfahren zur verwendung
EP3134121A4 (de) Neuartige anti-rnf43-antikörper und verfahren zur verwendung
EP3491025A4 (de) Fcrn-antikörper und verfahren zur verwendung davon
EP3280440A4 (de) Humanisierte anti-c1s-antikörper und verfahren zur verwendung davon
EP3728323A4 (de) Anti-frizzled-antikörper und verfahren zur verwendung
EP3559042A4 (de) Anti-lilrb3-antikörper und verfahren zur verwendung davon
EP3189079A4 (de) Neuartige anti-mfi2-antikörper und verfahren zur verwendung
IL265957A (en) Anti-c1s antibodies and methods of using them
EP3684819A4 (de) Anti-ykl40-antikörper und verfahren zur verwendung
EP3710589A4 (de) Anti-c1s-antikörper und verfahren zur verwendung

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190117

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20191210

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/18 20060101AFI20191204BHEP

Ipc: A61P 7/00 20060101ALI20191204BHEP

Ipc: C12N 15/09 20060101ALI20191204BHEP

Ipc: A61K 39/395 20060101ALI20191204BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20220923